Day: November 19, 2025

Continued Focus on Operational Execution and Strategic Transformation SKOKIE, Ill., Nov. 19, 2025 (GLOBE NEWSWIRE) — LanzaTech Global, Inc. (NASDAQ: LNZA) (“LanzaTech” or the “Company”), a carbon management solutions company, today reported its financial and operating results for the third quarter ended September 30, 2025. Key Highlights:First Commercial Ethanol-to-Jet Plant Operational: In November 2025, LanzaJet, Inc., a sustainable aviation fuel (“SAF”) joint venture entity in which the Company has a 36.33% equity interest, began fully operating and producing fuels at its LanzaJet Freedom Pines Fuels facility in Soperton, Georgia, USA – marking both the world’s first production at a commercial-scale plant of jet fuel using ethanol as a feedstock, and the first renewable solution, compatible with today’s aircraft,...

All figures in $USD unless otherwise noted. TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) — Firm Capital Apartment Real Estate Investment Trust (the “Trust”), (TSXV: FCA.U), (TSXV: FCA.UN) is pleased to provide a Strategic Review update, accretive Texas property refinancing and financial results for the three and nine months ended September 30, 2025: STRATEGIC REVIEW UPDATE Since November 15, 2022, the Trust has been under a strategic review process to identify, evaluate and pursue a range of strategic alternatives with the goal of maximizing unitholder value (the “Strategic Review”). By way of update, the Board of Trustees of the REIT have confirmed that no further growth will occur in the US under the current platform. As such, the Board will pursue the following strategy: (i) sell and exit all current investments, and return cash...

ROANOKE, Va., Nov. 19, 2025 (GLOBE NEWSWIRE) — RGC Resources, Inc. (Nasdaq: RGCO) announced consolidated Company earnings of $13.3 million, or $1.29 per share, for the fiscal year ended September 30, 2025, compared to $11.8 million, or $1.16 per share, for the fiscal year ended September 30, 2024. The strong increase reflected record levels of gas deliveries aided by higher operating margins, partially offset by inflationary cost increases and lower equity earnings from the Company’s investment in the Mountain Valley Pipeline (MVP). MVP’s equity earnings in the first three quarters of fiscal 2024 contained significant allowance for funds used during construction. Roanoke Gas made further investments in its utility infrastructure to drive customer growth and enhance system reliability. CEO Paul Nester stated, “We delivered gas effectively...

Net loss on a GAAP basis was $7.9 million for the current quarter and $14.7 million on a year-to-date basis, inclusive of various non-cash charges.  Net loss on a non-GAAP basis was $1.3 million for the current quarter and $3.6 million for the current year-to-date. Current quarter Adjusted EBITDA for 2025 was negative $0.65 million, compared with Adjusted EBITDA of negative $1.05 million for the comparable nine-month period in 2024, representing a 38% improvement. Year-to-Date Adjusted EBITDA for 2025 was negative $1.65 million, compared with Adjusted EBITDA of negative $2.6 million for the comparable nine-month period in 2024, representing a 38% improvement.NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB) (“Xcel” or the “Company”), a media and consumer products company with significant expertise...

OWINGS MILLS, Md., Nov. 19, 2025 (GLOBE NEWSWIRE) — Universal Safety Products, Inc. (NYSE AMEX: UUU) today announced results for its fiscal second quarter and six months ended September 30, 2025. For the three months ended September 30, 2025, sales decreased 89.4% to $759,999 compared to sales of $7,203,269 for the same period last year. The Company reported a net loss of $999,780, or $0.43 per basic and diluted share, compared to net income of $576,978 or $0.25 per basic and diluted share for the same period last year. For the six months ended September 30, 2025, sales decreased 61.2% to $4,584,246 versus $11,801,785 for the same period last year. The Company reported net income of $810,541, or $0.35 per basic share and $0.33 per diluted share, compared to net income of $134,772 or $0.06, per basic and diluted share for the corresponding...

PANAMA CITY, Nov. 19, 2025 (GLOBE NEWSWIRE) — Copa Holdings1, S.A. (NYSE: CPA), today announced financial results for the third quarter of 2025 (3Q25), delivering another quarter of strong profitability and operational excellence. Key highlights for the quarter include:Net profit of US$173.4 million or US$4.20 per share, compared to US$146.0 million or US$3.50 per share in 3Q24, representing year-over-year increases of 18.7% and 20.1%, respectively. Operating margin of 23.2% and net margin of 19.0%, an increase of 2.9 and 1.9 percentage points, respectively, compared to 3Q24. Load factor increased 1.8 percentage points year over year to 88.0% and capacity, measured in available-seat-miles (ASM), increased 5.8% compared to 3Q24. Revenue per available seat mile (RASM) of 11.1 cents, up 1.0% year-over-year. Operating cost per available...

Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today reported financial results and operating highlights for the three and nine months ended September 30, 2025. Kirk Huntsman, Vivos’ Chairman...

ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases. The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS) with potential indication expansion in Alport syndrome and diabetic kidney disease. The lead indication for IC 100 is cardiometabolic conditions, with potential indication expansion in rare kidney diseases. Raised approximately $2.05 million in Q3-2025; $4.05 million year-to-date.WESTON, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (OTCQB: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment...